Viatris Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Viatris Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.30B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.74B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $15.43B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $16.26B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $17.89B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $11.95B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $11.50B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $11.43B | Mar 1, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.69B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $15.39B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $16.22B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $17.81B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $11.82B | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $0 | May 7, 2020 |
| FY2020 | Dec 31, 2018 | $11.27B | Mar 1, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.01B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.62B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $6.44B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $6.50B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $5.58B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.80B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.90B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $4.00B | Mar 1, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | May 7, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.66B) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $10.10M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $766.20M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.61B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($34.00M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($210.80M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $715.50M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $905.60M | Mar 1, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $751.10M | Feb 28, 2022 |
| FY2021 | Dec 31, 2020 | $555.10M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $639.90M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $704.50M | Mar 1, 2021 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.79B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $4.10B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $4.07B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.18B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $4.53B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $3.34B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $2.56B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $2.44B | Mar 1, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.30B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.90B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $3.00B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $3.02B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.23B | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $0 | May 7, 2020 |
| FY2020 | Dec 31, 2018 | $2.34B | Mar 1, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $378.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $326.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $377.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $406.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $457.20M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $243.00M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $213.20M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $252.10M | Mar 1, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.19B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $41.50B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $47.69B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $50.02B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $54.84B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $61.55B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $31.26B | Mar 1, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.48B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $22.87B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $27.22B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $28.95B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $34.35B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $38.60B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $19.37B | Mar 1, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | May 7, 2020 |
| FY2019 | Feb 13, 2019 | $0 | May 7, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.75B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.13B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $9.87B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $10.43B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $12.11B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $12.35B | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $9.59B | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $9.75B | Mar 1, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($388.30M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.42B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.64B | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $5.18B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.69B | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $5.36B | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $6.03B | Mar 1, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $734.80M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $991.90M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.26B | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $701.20M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $844.40M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $475.60M | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | $388.10M | Mar 1, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | 0 | May 7, 2020 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Feb 28, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | 100 | May 7, 2020 |